z-logo
open-access-imgOpen Access
Impact of a non‐fluoridated microcrystalline hydroxyapatite dentifrice on enamel caries progression in highly caries‐susceptible orthodontic patients: A randomized, controlled 6‐month trial
Author(s) -
Schlagenhauf Ulrich,
Kunzelmann KarlHeinz,
Hannig Christian,
May Theodor W.,
Hösl Helmut,
Gratza Mario,
Viergutz Gabriele,
Nazet Marco,
Schamberger Sebastian,
Proff Peter
Publication year - 2019
Publication title -
journal of investigative and clinical dentistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.599
H-Index - 21
eISSN - 2041-1626
pISSN - 2041-1618
DOI - 10.1111/jicd.12399
Subject(s) - dentifrice , dentistry , medicine , toothpaste , randomized controlled trial , fluoride , enamel paint , orthodontics , surgery , chemistry , inorganic chemistry
Aim The aim of the present randomized, controlled trial was to compare the impact of the regular use of a fluoride‐free microcrystalline hydroxyapatite ( HAP ) dentifrice and a 1400 ppm fluoride control dentifrice on caries progression in 150 highly caries‐active orthodontic patients. Methods The primary outcome was the occurrence of lesions with International Caries Detection and Assessment System ( ICDAS ) ≥code 1 on the vestibular surfaces of teeth 15‐25 within 168 days after fixation of orthodontic brackets. Secondary outcomes were lesion development ICDAS ≥code 2, the plaque index, and the gingival index. Results In total, 147 patients were included in the intent‐to‐treat ( ITT ) analysis; 133 finished the study per protocol ( PP ). An increase in enamel caries ICDAS ≥code 1 was observed in 56.8% ( ITT ) and 54.7% ( PP ) of the HAP group participants compared with 60.9% ( ITT ) and 61.6% ( PP ) of the fluoride control group. Non‐inferiority testing ( ITT and PP ) demonstrated the absence of a significant difference between the groups. No significant differences in secondary outcomes were observed between the groups. Conclusion In highly caries‐active patients, the impact of the regular use of a microcrystalline HAP dentifrice on caries progression is not significantly different from the use of a 1400 ppm fluoride toothpaste (ClinicalTrials.gov: NCT 02705456).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here